TY - JOUR
T1 - Prevalence and Risk Factors for Hyposalivation and Xerostomia in Childhood Cancer Survivors Following Different Treatment Modalities-A Dutch Childhood Cancer Survivor Study Late Effects 2 Clinical Study (DCCSS LATER 2)
AU - DCCSS LATER Study Group
AU - Stolze, Juliette
AU - Teepen, Jop C
AU - Raber-Durlacher, Judith E
AU - Loonen, Jacqueline J
AU - Kok, Judith L
AU - Tissing, Wim J E
AU - de Vries, Andrica C H
AU - Neggers, Sebastian J C M M
AU - van Dulmen-den Broeder, Eline
AU - van den Heuvel-Eibrink, Marry M
AU - van der Pal, Helena J H
AU - Versluys, A Birgitta
AU - van der Heiden-van der Loo, Margriet
AU - Louwerens, Marloes
AU - Kremer, Leontien C M
AU - Brand, Henk S
AU - Bresters, Dorine
PY - 2022/7/11
Y1 - 2022/7/11
N2 - Background: Limited data are available on the risk factors of salivary gland dysfunction in long-term childhood cancer survivors (CCS). The objective of this cross-sectional study, part of the multidisciplinary multicenter Dutch CCS Study Late Effects 2 (DCCSS LATER 2), was to assess the prevalence of and risk factors for hyposalivation and xerostomia in CCS. Methods: From February 2016 until March 2020, 292 CCS were included. Data with regard to gender, age at study, diagnosis, age at diagnosis, and treatment characteristics were collected, as well as the unstimulated (UWS) and stimulated whole salivary flow rate (SWS). Xerostomia was assessed with the Xerostomia Inventory (XI) questionnaire. Multivariable Poisson regression analyses were used to evaluate the association between potential risk factors and the occurrence of hyposalivation. Results: The minimum time between diagnosis and study enrollment was 15 years. The prevalence of hyposalivation was 32% and the prevalence of xerostomia was 9.4%. Hyposalivation and xerostomia were not significantly correlated. Risk factors for hyposalivation were female gender and a higher dose of radiotherapy (>12 Gy) to the salivary gland region. Conclusion: Considering the importance of saliva for oral health, screening for hyposalivation in CCS is suggested in order to provide optimal oral supportive care aimed to improve oral health.
AB - Background: Limited data are available on the risk factors of salivary gland dysfunction in long-term childhood cancer survivors (CCS). The objective of this cross-sectional study, part of the multidisciplinary multicenter Dutch CCS Study Late Effects 2 (DCCSS LATER 2), was to assess the prevalence of and risk factors for hyposalivation and xerostomia in CCS. Methods: From February 2016 until March 2020, 292 CCS were included. Data with regard to gender, age at study, diagnosis, age at diagnosis, and treatment characteristics were collected, as well as the unstimulated (UWS) and stimulated whole salivary flow rate (SWS). Xerostomia was assessed with the Xerostomia Inventory (XI) questionnaire. Multivariable Poisson regression analyses were used to evaluate the association between potential risk factors and the occurrence of hyposalivation. Results: The minimum time between diagnosis and study enrollment was 15 years. The prevalence of hyposalivation was 32% and the prevalence of xerostomia was 9.4%. Hyposalivation and xerostomia were not significantly correlated. Risk factors for hyposalivation were female gender and a higher dose of radiotherapy (>12 Gy) to the salivary gland region. Conclusion: Considering the importance of saliva for oral health, screening for hyposalivation in CCS is suggested in order to provide optimal oral supportive care aimed to improve oral health.
KW - cancer survivors
KW - childhood cancer
KW - decreased salivary flow rate
KW - hyposalivation
KW - late effects
KW - oral health
KW - salivary gland dysfunction
KW - xerostomia
UR - https://www.mendeley.com/catalogue/40959353-f687-303b-8213-a0891b8130a7/
U2 - 10.3390/cancers14143379
DO - 10.3390/cancers14143379
M3 - Article
C2 - 35884440
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 14
ER -